Back to Trasylol®

Bayer recently reported a strong set of financials for its healthcare division which suggests that the firm's acquisition of Schering AG is going to prove to be a good investment.

There was one blot on the financials, however, with the performance of Trasylol® (aprotinin), which is used to reduce blood loss during heart surgery. Revenues fell 33.5% to 153 million euros, hurt by the Food and Drug Administration's insistence on a new label which highlights the possible risk of kidney damage associated with the use of Trasylol®.

This came after Bayer had been late on providing new data on Trasylol® to the FDA, which led to the company setting up an external investigation.

At the beginning of this year, further negative data on Trasylol® was published in the Journal of American Medical Association, stating that patients had a 50 percent higher chance of dying within the first five years after their heart surgery. Bayer still rejects it as unreliable and maintains Trasylol® is a safe when used correctly.

If you or someone you know has undergone a coronary artery bypass grafting surgery and subsequently developed the onset of kidney failure, please use the form on the left to contact our law firm.

Reference:

"Bayer has high hopes that cancer drug Nexavar will be huge," PharmaTimes, Kevin Grogan, March 2007.